NOWDx Test for the Detection of Antibodies to COVID-19

Completed · Not applicable

Conditions studied: COVID-19, SARS-CoV-2, Coronavirus

In brief

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (venous and fingerstick).

Key facts

Study ID

NCT04690413

Run by

NOWDiagnostics, Inc.

People needed

129

Starts

2020-09-01

Expected to finish

2020-12-31

Last updated by the study team

2024-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Persons ≥18 years old;
• Persons who have tested positive or negative (within 6 days) for COVID-19 with an emergency use authorized molecular (PCR) test and can furnish said test report.

You may not qualify if…

• Persons <18 years old;
• Persons who have previously participated in a NOWDx study.

Where it is running

• Del Sol Research Management, LLC — Tucson, Arizona, United States
• Comprehensive Clinical Research, LLC — West Palm Beach, Florida, United States
• Clinical Research Solutions, LLC — Jackson, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.